T cells are a natural part of the immune system designed to fight infections and cancer, but in conditions like blood cancer, they may not be able to eliminate malignant cells, according to Dr.

T Cell Engagers (TCEs) are bispecific antibodies that target both tumor-associated cell surface antigens (TAA) and T-cell surface receptors (TCR). TCE bispecific antibodies have a major advantage over ...

The study reviews CAR-T cell advancements in lymphoma treatment, addressing T cell exhaustion and tumor immune evasion with ...

HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

In 2022, there were 2.3 million women diagnosed with breast cancer and 670,000 deaths worldwide, according to the World ...

Eight researchers specializing in adult oncology from Fred Hutch Cancer Center and the University of Washington have been ...

An expert highlights that the future of metastatic castration-resistant prostate cancer (mCRPC) treatment is advancing with novel drug classes such as radioligand therapies, proteolysis-targeting ...

A series of new peptides (8−25) containing different unnatural amino acids of the adamantane type (1−6), was synthesized. Possible cytotoxic activity on human cervical adenocarcinoma (HeLa), larynx ...

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The ...

New trial results reveal zanzalintinib and atezolizumab significantly enhance survival in metastatic colorectal cancer, ...